Recombinant Human PDCD1 Protein，His

Programmed cell death protein 1 (PDCD1), commonly known as PD-1, is an important inhibitory receptor that plays a critical role in regulating the immune system and maintaining immune tolerance. It is predominantly expressed on the surface of T cells and other immune cells, where it helps prevent autoimmunity by downregulating the immune response. The engagement of PD-1 with its ligands, PD-L1 and PD-L2, can lead to the inhibition of T cell activation and proliferation, making this pathway a significant focus of cancer immunotherapy research. As tumors often exploit the PD-1/PD-L pathway to evade immune detection, the study of PDCD1 recombinant proteins has gained traction in recent years. By producing these recombinant proteins, researchers can investigate the molecular mechanisms underlying the PD-1 signaling pathway, evaluate potential therapeutic antibodies, and develop strategies to enhance anti-tumor immunity. Furthermore, the development of PD-1 inhibitors, such as monoclonal antibodies targeting PD-1, has revolutionized cancer treatment, demonstrating robust efficacy in various malignancies. The ongoing research into PDCD1 and its recombinant proteins not only furthers our understanding of immune regulations but also paves the way for novel therapeutic interventions aimed at reactivating T cell responses in the tumor microenvironment.